Galina Lurie

Summary

Affiliation: University of Hawaii
Country: USA

Publications

  1. request reprint
    Lurie G, Maskarinec G, Kaaks R, Stanczyk F, Le Marchand L. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14:1521-7 pubmed
    ..37 versus 1.76; P = 0.002). These data suggest that CYP1A2*1F is associated with lower circulating levels of E2, and that it may be a susceptibility locus for breast cancer. ..
  2. request reprint
    Lurie G, Wilkens L, Thompson P, McDuffie K, Carney M, Terada K, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2566-71 pubmed
    ..1 and OR 5.2, 95% CI 1.6-17.5), but not in Japanese women (OR 1.1, 95% CI 0.6-1.9 and OR 2.3, 95% CI:0.4-12.3). This investigation provides some evidence that polymorphisms in the VDR gene might influence ovarian cancer susceptibility...
  3. Lurie G, Wilkens L, Thompson P, Carney M, Palmieri R, Pharoah P, et al. Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. Int J Cancer. 2011;128:936-43 pubmed publisher
    ..46), tumor histology (p = 0.98), or time between diagnosis and interview (p = 0.94). This pooled analysis provides further evidence that the VDR rs2228570 polymorphism might influence ovarian cancer susceptibility. ..
  4. Lurie G, Terry K, Wilkens L, Thompson P, McDuffie K, Carney M, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control. 2010;21:1731-41 pubmed publisher
    ..43; CI:0.20-0.93) in all women combined. The association of PTGS2 rs5275 with nonserous ovarian carcinoma and possible effect modification by NSAID use needs further validation, preferably in prospective studies. ..
  5. Lurie G, Wilkens L, Thompson P, Shvetsov Y, Matsuno R, Carney M, et al. Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. PLoS ONE. 2011;6:e20703 pubmed publisher
    ..This pooled analysis suggests that rs1271572 might influence the risk of ovarian cancer, in particular among younger women. ..

Locale

Collaborators

Detail Information

Publications5

  1. request reprint
    Lurie G, Maskarinec G, Kaaks R, Stanczyk F, Le Marchand L. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14:1521-7 pubmed
    ..37 versus 1.76; P = 0.002). These data suggest that CYP1A2*1F is associated with lower circulating levels of E2, and that it may be a susceptibility locus for breast cancer. ..
  2. request reprint
    Lurie G, Wilkens L, Thompson P, McDuffie K, Carney M, Terada K, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2566-71 pubmed
    ..1 and OR 5.2, 95% CI 1.6-17.5), but not in Japanese women (OR 1.1, 95% CI 0.6-1.9 and OR 2.3, 95% CI:0.4-12.3). This investigation provides some evidence that polymorphisms in the VDR gene might influence ovarian cancer susceptibility...
  3. Lurie G, Wilkens L, Thompson P, Carney M, Palmieri R, Pharoah P, et al. Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. Int J Cancer. 2011;128:936-43 pubmed publisher
    ..46), tumor histology (p = 0.98), or time between diagnosis and interview (p = 0.94). This pooled analysis provides further evidence that the VDR rs2228570 polymorphism might influence ovarian cancer susceptibility. ..
  4. Lurie G, Terry K, Wilkens L, Thompson P, McDuffie K, Carney M, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control. 2010;21:1731-41 pubmed publisher
    ..43; CI:0.20-0.93) in all women combined. The association of PTGS2 rs5275 with nonserous ovarian carcinoma and possible effect modification by NSAID use needs further validation, preferably in prospective studies. ..
  5. Lurie G, Wilkens L, Thompson P, Shvetsov Y, Matsuno R, Carney M, et al. Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. PLoS ONE. 2011;6:e20703 pubmed publisher
    ..This pooled analysis suggests that rs1271572 might influence the risk of ovarian cancer, in particular among younger women. ..